"As a world leader in the production of stable isotope applications, CIL understands that developing and commercializing innovative products in an efficient, cost-effective and compliant manner requires an entirely new approach to the lab-to-commercialization process," said Ken Rapp, managing director of Accelrys' analytical, development, quality and manufacturing solutions group. "By connecting lab-to-plant workflows and taking a process- and execution-centric approach to LIMS implementations, CIL benefits from the flexibility needed to manage its rapidly growing business and the highly efficient process execution required to produce quality cGMP products." CIL develops, produces and markets stable, non-radioactive isotopes and chemical components for the specialty chemicals, research products, environmental standards and clinical research industries. Producing products that meet cGMP requirements is essential to its business. GMP compliance is an expensive and time-consuming practice, and with customer demand driving increasing production, CIL's manual processes were no longer keeping pace with the company's needs.
Accelrys ACCL was soaring nearly 30% to $12.55, its highest point in nearly ten years, on Thursday after news broke that Dassault Systemes would buy the software company for approximately $750 million. Dassault, a software company based in France that designs programs with the aid of computers, announced that it would purchase the San Diego-based Accelrys for $12.50 a share and would make an all-cash tender offer. Accelrys' board has unanimously approved the merger, according to Dassault's statement.